Edition:
United States

PureTech Health PLC (PRTC.L)

PRTC.L on London Stock Exchange

128.00GBp
18 Oct 2017
Change (% chg)

-- (--)
Prev Close
128.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
32,292
52-wk High
139.75
52-wk Low
110.00

Latest Key Developments (Source: Significant Developments)

PureTech initiates phase 2b inhibitors study in respiratory tract infections
Tuesday, 9 May 2017 02:00am EDT 

May 9 (Reuters) - PureTech Health Plc ::PureTech initiates phase 2b mtorc1 study in rtis.Announces initiation of phase 2b mtorc1 inhibitors study in elderly patients at increased risk of respiratory tract infections.Study builds on efficacy and safety data from previous phase 2 clinical studies, which suggest selective targeting of mtorc1.  Full Article

PureTech Health's Akili announces pilot study results
Thursday, 6 Apr 2017 02:00am EDT 

PureTech Health Plc : PureTech's Akili announces pilot study results .Results from project EVO pilot study showed improved cognitive control in children with sensory processing dysfunction, attentional deficits.  Full Article

Puretech Health appoints Bharatt Chowrira as president and chief of business and strategy
Thursday, 2 Mar 2017 02:00am EST 

Puretech Health Plc :Appoints Bharatt Chowrira, PH.D., J.D., as president and chief of business and strategy.  Full Article

PureTech's Akili adds two pharma venture funds to series B financing
Wednesday, 20 Jul 2016 02:00am EDT 

Puretech Health Plc :Puretech's Akili adds two pharma venture funds to series b financing, increasing round to $42.4 million.  Full Article

BRIEF-PureTech affiliate Gelesis reports weight loss in study

* ‍gelesis reports significant weight loss with excellent safety profile in pivotal study with gelesis100​